Current treatment options for perinatal depression

PURPOSE OF REVIEW: Perinatal depression (PND) affects up to one in five patients and is the leading cause of maternal mortality, yet remains underdiagnosed and undertreated. This review provides an updated, clinically relevant synthesis on screening, treatment, and emerging therapies. RECENT FINDINGS: Current guidelines recommend universal PND screening using validated tools. Selective serotonin reuptake inhibitors remain the first-line pharmacological treatment, with updated data supporting their safety in pregnancy and lactation. New agents like zuranolone, the first oral neurosteroid for postpartum depression, offer rapid symptom relief. Interventional psychiatry tools, including ketamine, esketamine, transcranial magnetic stimulation, and electroconvulsive therapy, may benefit select patients. Digital tools and artificial intelligence show promise for early detection and tailored interventions but require further validation. SUMMARY: Timely diagnosis and individualized treatment of PND are essential for optimizing maternal and neonatal outcomes. Individualized, evidence-based treatment, including pharmacologic and nonpharmacologic options, can improve outcomes for both the parent and fetus or infant. New therapies and digital innovations hold promise but require careful integration into practice.